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ABSTRACT 
Accurate early diagnosis and monitoring of 
neurodegenerative conditions is essential for effective disease 
management and treatment. This research develops automatic 
methods for detecting brain imaging preclinical biomarkers 
for olfactory dysfunction in early stage Parkinson’s disease 
(PD) by considering the novel application of evolutionary 
algorithms. Classification will be applied to PD patients with 
severe hyposmia, patients with no/mild hyposmia, and 
healthy controls. An additional novel element is the use of 
evolutionary algorithms to map and predict the functional 
connectivity using rs-fMRI. Cartesian Genetic Programming 
(CGP) will be used to classify dynamic causal modelling (DCM) 
data as well as timeseries data. The findings will be validated 
using two other commonly used classification methods (ANN 
and SVM) and by employing k-fold cross-validation. 
Developing methods for identifying early stage PD patients 
with hyposmia is relevant since current methods of 
diagnosing early stage PD have low reliability and accuracy. 
Furthermore, exploring the performance of CGP relative to 
other methods is crucial given the additional benefits it 
provides regarding easy classifier decoding. Hence, this 
research underscores the potential relevance of DCM analyses 
for classification and CGP as a novel classification tool for 
brain imaging data with medical implications for disease 
diagnosis, particularly in early stages. 
CCS CONCEPTS 
• Computing methodologies → Machine Learning → 
Learning Paradigms → Supervised Learning → Supervised 
Learning by Classification 
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1 INTRODUCTION 
There is poor differential diagnosis of neurodegenerative 
diseases with high rates of misdiagnosis and low test-retest 
reliability [1]; indeed, PD has rates of misdiagnosis of 15-26%. 
Hence, this research examines a key question: Can early stage 
PD be diagnosed using EAs on rs-fMRI data? Early diagnosis of 
PD is fundamental in providing patients with palliative care 
during the early phases before motor symptoms are present, 
enabling effective disease management and maintaining 
patient quality of life. Moreover, once a neuroprotective drug 
to treat PD is developed, the early diagnosis of PD would have 
even greater clinical implications [2]. 
This research explores an automatic and non-invasive 
method of confirming the diagnosis of PD, specifically, 
examining the classification of PD patients with severe 
hyposmia (olfactory dysfunction), patients with no/mild 
hyposmia, and healthy controls. This research will involve an 
analysis of rs-fMRI data taken from the OpenfMRI (accession 
number: ds000245). This study will apply EAs (CGP and 
RCGP) for the classification of rs-fMRI in PD using DCM and 
timeseries analyses. The timeseries values and DCM values 
from the rs-fMRI data will be subjected to supervised 
classification and the findings will be validated with two other 
commonly used classification methods (ANN and SVM) as well 
as employing k-fold CV. 
A key aim of this research is to identify the applicability of 
CGP and RCGP classification for both timeseries and DCM 
analyses regarding the analysis of PD data. CGP and RCGP 
have not previously been used in the classification of brain 
imaging data. This study examines an additional novel 
question: is DCM analysis useful for classification for PD data? 
Previous research has not explored the applicability of DCM 
values in classification and, to date, little research has applied 
DCM to PD data [3]. Hence, by doing both, this research 
develops automatic procedures for identifying PD brain 
imaging preclinical biomarkers for olfactory dysfunction, 
which can be used for aiding/confirming early PD diagnosis. 
Based on previous work from the authors revealing 
classification accuracies of up to 92% for identifying a 
biomarker for early stage PD, it is expected that evolutionary 
algorithms can be applied to olfactory dysfunction for PD 
patients with similarly high accuracies. 
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2 EXPERIMENTAL AND COMPUTATIONAL DETAILS 
2.1 Participants 
Forty-five participants were recruited with an age range of 
52–78 years (20 male): 15 PD patients with severe hyposmia, 
15 patients with no/mild hyposmia, and 15 healthy controls 
were examined. Brain atrophic changes and functional 
connectivity alterations in all participants were evaluated 
using Odour Stick Identification Test for the Japanese and 
Addenbroke’s Cognitive Examination Revised for their odour-
identification performance and general cognitive function, 
respectively. The study was approved by the institutional 
review board of participating sites. Written informed consent 
was obtained from all participants. 
2.2 Classification 
To have equal class representation, data from each class 
will be divided randomly into subsets of 70% (training), 15% 
(validation), and 15% (test). The geometry of the programs in 
the population (chromosomes) has fifty nodes with a function 
set of four mathematical operations (+, -, ×, ÷), multiple 
inputs (according to the datasets), and one output (class 1 for 
one participant group, class 0 for the other participant group). 
At each generation, the fittest chromosome is selected and the 
next generation is formed with its mutated versions (mutation 
rate = 0.1). Evolution stops when 15000 iterations are 
reached. To obtain statistical significance, the classification 
will be done in 10 runs for each combination of inputs and the 
accuracy was averaged over the runs. The results (the winning 
chromosome, the networks, and the accuracy values) will be 
stored for each run individually. 
One of the core advantages of CGP is that it provides a 
white box solution, giving more information on the inputs used 
and enhanced knowledge concerning the final solution 
obtained in classification, which is not easily possible (if at all) 
with ANN and SVM classification techniques. The classification 
will be done using CGP, ANN, and SVM (the latter two being 
used to validate the classification results from CGP). 
2.3.1 Classification of the DCM values. 
Following preprocessing and processing the fMRI data, 
DCM analysis results will be subjected to classification 
implemented in CGP and RCGP. One group of participants will 
be assigned class 0 and a different group will be assigned class 
1. To have equal class representation, data from each class 
will be divided randomly into subsets of 70% (training), 15% 
(validation), and 15% (test). The classification will be run in 
the CGP Library with 16 inputs (all the DCM values sorted by 
region and presented as only one vector per participant, see 
Figure 1), 50 nodes, 1 output (class 1 for one group, class 0 for 
the other one), and 15000 generations. The process will be 
repeated for 10 runs and the results (the winning 
chromosome, the networks, and the accuracy values) will be 
stored for each run individually. To facilitate comparison, 
classification with data from the same participants will be run 
using ANN and SVM. 
 
Figure 1: Default mode network and 
the four regions of interest used in 
the DCM analysis. 
2.3.2 k-fold Cross-Validation (CV). 
10-fold CV will be used to evaluate 
classification accuracy using an 
unbiased estimate of the generalisation accuracy [4]. CV is 
beneficial as it allows the generation of independent test sets 
with enhanced reliability. 10-fold CV is repeated 10 
independent times and the mean accuracy over all 10 trials is 
calculated. 
3 RESULTS 
Provisional results revealed that the CGP classifiers had an 
accuracy rate of 90% for classifying PD patients with severe 
hyposmia from healthy controls. The results from two other 
classification techniques (ANN and SVM) validated this finding 
as they were very similar. 
4 CONCLUSIONS 
To conclude, this research explores the classification of rs-
fMRI data in early stage PD patients with severe hyposmia, 
patients with no/mild hyposmia, and healthy controls using 
novel data (DCM analyses) and a novel classification method 
(CGP). Classification accuracy for DCM analyses will be 
compared to that of timeseries analyses, and two other 
classification methods (ANN and SVM) will be used to validate 
the findings, as well as k-fold cross-validation. Hence, this 
research underscores the potential relevance of CGP as a 
classification tool for two types of brain imaging data (DCM 
and timeseries rs-fMRI analyses) and develops automatic 
procedures for identifying PD brain imaging preclinical 
biomarkers for olfactory dysfunction, which are fundamental 
in improving accuracy of early stage PD diagnosis methods. 
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